Mild Cognitive Impairment (MCI)SuperBrainBOOMNCT07101380
Feasibility Study of 'SuperBrain BOOM' for Mild Cognitive Impairment Patients
A study testing Tablet-based Physical SuperBrain BOOM and Smartphone-based SuperBrain BOOM in people with Mild Cognitive Impairment (MCI), run by Ajou University School of Medicine at 4 sites in South Korea.
Trial summary
The goal of this clinical trial is to learn whether a mobile-based personalized physical activity program called SuperBrain BOOM is safe and works to improve cognitive function, physical performance, mood, and quality of life in older adults (ages 50-85) with mild cognitive impairment (MCI). Read more about this study
- Who is it for?
- Ages 50 to 85 years
- Conditions the study is for
- Mild Cognitive Impairment (MCI)
- What is being tested?
- Tablet-based Physical SuperBrain BOOM and Smartphone-based SuperBrain BOOM
- Type of treatment
- Pill or oral medicine, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 45 participants
- Where
- 4 sitesSouth Korea
- Study dates
- 23 Feb 2026to 9 Sep 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age: Between 50 and 85 years old.
- Meets all of the core clinical criteria for suspected Mild Cognitive Impairment (MCI) according to the National Institute on Aging-Alzheimer's Association (NIA-AA) guidelines as of the screening date:
- Concerns of the participant or caregiver regarding cognitive decline compared to prior functioning.
- Impairment in at least one cognitive domain.
- Preserved independence in overall daily living activities.
- No dementia.
Show all 16Show fewer
- Has one or more of the following neuropsychological test results within one year of the screening date, with delayed recall scores in the memory domain below the mean -1.0 standard deviation according to age- and education-adjusted normative data:
- Seoul Neuropsychological Screening Battery 2nd Edition (SNSB-II)
- Korean version of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD-K)
- Literacy Independent Cognitive Assessment (LICA)
- As of the screening date, has a Korea-Mini Mental State Examination (K-MMSE-2) score that corresponds to at least -1.5 standard deviations below the mean based on age- and education-adjusted normative data.
- As of the screening date, has a Global Clinical Dementia Rating (CDR) score of 0.5, with a memory score of either 0.5 or 1.
- Capable of using a tablet or smartphone with training, or has a research partner who can assist with using a tablet or smartphone.
- Has a caregiver who regularly contacts the participant:
- -A caregiver who is able to support the participant (monitor compliance and report participant status) and spends at least 8 hours per week with the participant during the trial period.
- The participant provides written informed consent to participate in the study.
Who cannot join
- Presence of psychiatric disorders, such as major depression.
- Dementia.
- Other neurodegenerative diseases, such as Parkinson's disease.
- Malignant tumors within the past 5 years that have not been declared cured.
- Vascular surgery or stent placement within the past year.
- Severe or unstable symptomatic cardiovascular disease.
Show all 12Show fewer
- Evidence of severe or unstable physical conditions, such as acute or severe asthma, active peptic ulcers, severe liver disease, kidney disease requiring dialysis, or any other medical conditions that may interfere with completing the clinical trial.
- Severe vision impairment, severe hearing loss, or communication difficulties that would prevent the participant from undergoing the intervention or efficacy assessments.
- Abnormal findings in clinical pathology tests related to cognitive decline, as determined by the clinical investigator (e.g., significant thyroid dysfunction, vitamin B12 or folate deficiency, neurosyphilis, etc.).
- The investigator's judgment that the participant is unlikely to cooperate fully with the study.
- The investigator's judgment that the participant has difficulty safely participating in an exercise-based intervention program.
- Participation in another interventional clinical trial.
Trial locations and contacts
4 sites in 1 country.
South Korea4 sites
Pusan National University Hospital
Busan
Chonnam National University Hospital
Gwangju
Bundang CHA General Hospital
Seongnam-si, Gyeonggi-do
Ajou University Hospital
Suwon, Gyeonggi-do, 16499
About this study
Official title: A Multicenter, Prospective, Randomized, Investigator- Initiated Exploratory Study to Evaluate the Efficacy on Cognitive Function and Safety of 'SUPERBRAIN BOOM' in Patients With Mild Cognitive Impairment
The goal of this clinical trial is to learn whether a mobile-based personalized physical activity program called SuperBrain BOOM is safe and works to improve cognitive function, physical performance, mood, and quality of life in older adults (ages 50-85) with mild cognitive impairment (MCI).
The main questions it aims to answer are:
Read more
Can SuperBrain BOOM be safely and effectively used by people with MCI? Does the program help improve cognitive and physical function? Do participants stay engaged and complete the program as expected?
Researchers will compare:
A mobile intervention group using SuperBrain BOOM (on tablet or smartphone) A control group receiving usual care
Participants will:
Use a tablet or smartphone to follow a personalized physical activity program for 12 weeks Complete clinical assessments on cognition, physical ability, mood, and nutrition Be monitored for safety and program adherence using automatically collected data
Read the detailed description
This study is designed to assess the feasibility, safety, and potential benefits of a multi-domain personalized physical activity intervention-SuperBrain BOOM-delivered via mobile devices (tablet or smartphone) for individuals with Mild Cognitive Impairment (MCI).
Mild Cognitive Impairment is a condition in which individuals experience noticeable cognitive decline without significant impairment in daily functioning. It is considered a transitional stage between normal aging and dementia. Evidence suggests that regular physical activity and cognitive engagement can delay or reduce the risk of progression to dementia.
SuperBrain BOOM provides personalized exercise programs tailored to each participant's cognitive status, physical capacity, and lifestyle, and is designed to improve cognitive function, physical performance, emotional well-being, and quality of life.
This randomized controlled trial will allocate participants into three groups: a mobile intervention group (tablet or smartphone) and a control group receiving usual care. The primary outcomes include changes in cognitive function, physical performance, mood, nutritional status, and quality of life over 12 weeks. Safety and adherence will be monitored throughout the intervention using system-generated data and clinical assessments.
Secondary analyses will explore subgroup differences based on APOE genotype and demographic variables to better understand who benefits most from the intervention.
- Conditions
- Mild Cognitive Impairment (MCI)
- Being tested
- Tablet-based Physical SuperBrain BOOM, Smartphone-based SuperBrain BOOM
- Keywords
- Mild Cognitive Impairment, MCI, Physical Activity, SuperBrain BOOM, Digital Health, Dementia Prevention
- Medical subject headings
- Cognitive Dysfunction, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tablet-based Physical SuperBrain BOOMDevice
This intervention is a tablet-based physical activity program designed for patients with Mild Cognitive Impairment (MCI).
Participants receive a personalized exercise plan through a tablet application, with real-time feedback to enhance cognitive function.
Compared to the smartphone-based version, this program is designed to provide a larger interface and structured environment, allowing participants to engage in the program using a tablet at home or in a clinical setting.
The app also helps track progress and encourage adherence to the exercise regimen.
Smartphone-based SuperBrain BOOMDevice
This intervention is a smartphone-based physical activity program designed for MCI patients. Participants receive a personalized exercise plan through a smartphone app, with real-time feedback to enhance cognitive function. Unlike the tablet-based intervention, this program is designed to be more portable and flexible, enabling participants to engage in the program from anywhere using their smartphones. The app also helps track progress and encourage adherence to the exercise regimen.
| Study group | Role | What they receive |
|---|---|---|
| Tablet-based intervention group | Experimental | Not described Receives: Device: Tablet-based Physical SuperBrain BOOM |
| Smartphone-based intervention group | Experimental | Not described Receives: Device: Smartphone-based SuperBrain BOOM |
| Control group | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14)
The ADAS-cog14 is a comprehensive cognitive assessment tool that includes memory, attention and concentration, planning and executive function, visuoconstruction, and orientation. Scores range from 0 to 90, with higher scores indicating worse cognitive function. The assessment will be conducted at baseline and at the end of the intervention (Week 12).
Measured: Baseline (Week 0, pre-intervention) and Week 12 (end of intervention)
Secondary outcomes (13)
Korean Mini-Mental State Examination, 2nd Edition (K-MMSE-2)
The Korean Mini-Mental State Examination, 2nd Edition (K-MMSE-2), is a brief cognitive screening tool widely used to assess general cognitive function. It evaluates orientation, memory, attention and calculation, visuospatial ability, and language through verbal and written tasks. Scores range from 0 to 30, with higher scores indicating better cognitive function. The assessment will be conducted at screening and at the end of the intervention (Week 12).
Measured: Screening (within 14 days prior to baseline) and Week 12 (end of intervention)
Clinical Dementia Rating scale - Sum of Boxes (CDR-SB)
The Clinical Dementia Rating scale - Sum of Boxes (CDR-SB) is used to assess the overall severity of dementia across six domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. The total score ranges from 0 to 18, with higher scores indicating more severe cognitive impairment. The assessment will be conducted at screening and at the end of the intervention (Week 12).
Measured: Screening (within 14 days prior to baseline) and Week 12 (end of intervention)
Korean Instrumental Activities of Daily Living (K-IADL)
The Korean Instrumental Activities of Daily Living (K-IADL) is an 11-item assessment tool used to evaluate functional independence in daily life activities, including telephone use, shopping, food preparation, housekeeping, and medication management. Each item is scored from 0 to 3, and a mean score of 0.4 or higher suggests possible dementia. Higher scores indicate greater impairment in instrumental activities of daily living. The assessment will be conducted at screening and at the end of the intervention (Week 12).
Measured: Screening (within 14 days prior to baseline) and Week 12 (end of intervention)
Timed Up and Go test
The Timed Up and Go (TUG) test is used to assess mobility and balance. Participants are seated on a chair placed 3 meters from a cone, with both feet on the ground and hands on their thighs. At the signal to start, they rise from the chair, walk to the cone, circle it, return, and sit down. After a demonstration and one practice trial, the test is performed twice, and the better of the two times (in 0.1-second units) is recorded. The assessment will be conducted at baseline and at the end of the intervention (Week 12).
Measured: Baseline (Week 0, pre-intervention) and Week 12 (end of intervention)
30-second Sit-to-Stand Test
The 30-second sit-to-stand test is used to assess lower body strength and endurance. Participants sit in a chair with arms crossed over the chest and hands resting on the shoulders. They are instructed to fully stand up and sit down as many times as possible within 30 seconds, keeping the knees, hips, and back extended. The number of repetitions is automatically recorded by the app. The test will be conducted at baseline and at the end of the intervention (Week 12).
Measured: Baseline (Week 0, pre-intervention) and Week 12 (end of intervention)
2-Minute Step Test
The 2-Minute Step Test is used to assess aerobic endurance. Participants are instructed to march in place for 2 minutes, lifting their knees to a height midway between the patella (kneecap) and iliac crest (hip). Each time the right knee reaches the required height, one count is recorded. The final score is calculated by dividing the total step count by 2. The test will be conducted at baseline and at the end of the intervention (Week 12).
Measured: Baseline (Week 0, pre-intervention) and Week 12 (end of intervention)
Quality of Life-Alzheimer's Disease (QOL-AD)
The Quality of Life-Alzheimer's Disease (QOL-AD) scale is a 13-item questionnaire designed to assess the quality of life in individuals with Alzheimer's disease. It includes both self-report from the participant and proxy-report from a caregiver. Total scores range from 0 to 52, with higher scores indicating better perceived quality of life. The assessment will be conducted at screening and at the end of the intervention (Week 12).
Measured: Screening (within 14 days prior to baseline) and Week 12 (end of intervention)
Nutritional Quotient for Elderly (NQ-E)
The Nutritional Quotient for Elderly (NQ-E) is a 20-item self-administered questionnaire developed to comprehensively assess dietary quality and nutritional status in older adults. Participants are asked to read and respond to items related to dietary behaviors, balance, diversity, moderation, and dietary environment. The total score ranges from 0 to 100, with higher scores indicating better nutritional status and quality of diet. The assessment will be conducted at baseline and at the end of the intervention (Week 12).
Measured: Baseline (Week 0, pre-intervention) and Week 12 (end of intervention)
Mini Nutritional Assessment (MNA)
The Mini Nutritional Assessment (MNA) is a validated screening tool for evaluating nutritional status in older adults. It includes questions on recent food intake, weight loss, mobility, psychological stress, and body mass index (BMI). The total score ranges from 0 to 14, with higher scores indicating better nutritional status. The assessment will be conducted at baseline and at the end of the intervention (Week 12).
Measured: Baseline (Week 0, pre-intervention) and Week 12 (end of intervention)
Assessment of Metabolic and Vascular Risk Factors
This assessment includes vital signs and anthropometric measurements (blood pressure, waist circumference, weight, body mass index), as well as lifestyle factors (alcohol consumption and smoking status). Additionally, blood tests will be conducted to evaluate metabolic and vascular risk markers, including fasting glucose, HbA1c, total cholesterol, triglycerides, HDL-C, LDL-C, BUN, and creatinine. Blood samples (8 cc) will be collected at screening and at the end of the intervention and analyzed by Seoul Clinical Laboratories. Higher levels of glucose, lipids, or renal markers may indicate elevated cardiometabolic risk.
Measured: Screening (within 14 days prior to baseline) and Week 12 (end of intervention)
Geriatric Depression Scale-15 items (GDS-15)
The Geriatric Depression Scale-15 items (GDS-15) is a self-report screening tool designed to assess depressive symptoms in older adults. Participants respond "yes" or "no" to 15 questions related to mood, energy, and interest. Total scores range from 0 to 15, with higher scores indicating greater severity of depressive symptoms. In the Korean validation study, a score of 8 or higher suggests the possibility of depression. The assessment will be conducted at screening and at the end of the intervention (Week 12).
Measured: Screening (within 14 days prior to baseline) and Week 12 (end of intervention)
Prospective and Retrospective Memory Questionnaire (PRMQ)
The Prospective and Retrospective Memory Questionnaire (PRMQ) is a 16-item self- and proxy-report questionnaire that assesses everyday memory performance. Each item is rated on a 5-point scale (1 to 5), with total scores ranging from 16 to 80. Lower scores indicate better memory function, while higher scores suggest more frequent memory failures. Both the participant and a caregiver will complete the questionnaire at screening and at the end of the intervention (Week 12).
Measured: Screening (within 14 days prior to baseline) and Week 12 (end of intervention)
Pittsburgh Sleep Quality Index (PSQI)
The Pittsburgh Sleep Quality Index (PSQI) is a 7-component self-report questionnaire used to assess subjective sleep quality over the past month. It evaluates sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Each component is scored from 0 to 3, and the total score ranges from 0 to 21. A total score of 8 or less indicates good sleep quality, while a score of 9 or higher suggests poor sleep quality. The assessment will be conducted at screening and at the end of the intervention (Week 12).
Measured: Screening (within 14 days prior to baseline) and Week 12 (end of intervention)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Aug 2025
- Study start23 Feb 2026
- Primary completion9 Sep 2026
- Study completion9 Sep 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mild Cognitive Impairment (MCI)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 45 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ajou University School of Medicine
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, So Young Moon, Ajou University School of Medicine
- Investigators
- So Young Moon, Principal investigator, Ajou University School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07101380
- Sponsor's protocol ID
- AJOUIRB-DE-2025-36
- Other IDs
- RS-2024-00337993
- Acronym
- SuperBrainBOOM
- Status last verified
- Oct 2026
- First submitted
- 25 Jul 2025
- Last updated
- 28 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Prospective, Randomized, Investigator- Initiated Exploratory Study to Evaluate the Efficacy on Cognitive Function and Safety of 'SUPERBRAIN BOOM' in Patients With Mild Cognitive Impairment
- ClinicalTrials.gov ID
- NCT07101380
- Acronym / sponsor ID
- SuperBrainBOOM / AJOUIRB-DE-2025-36
- Conditions
- Mild Cognitive Impairment (MCI)
- Keywords
- Mild Cognitive Impairment, MCI, Physical Activity, SuperBrain BOOM, Digital Health, Dementia Prevention
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 45 participants (actual)
- Lead sponsor
- Ajou University School of MedicineUniversity, hospital or other
- Study start
- 23 Feb 2026 (actual)
- Primary completion
- 9 Sep 2026 (actual)
- Study completion
- 9 Sep 2026 (actual)
- First posted
- 3 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn whether a mobile-based personalized physical activity program called SuperBrain BOOM is safe and works to improve cognitive function, physical performance, mood, and quality of life in older adults (ages 50-85) with mild cognitive impairment (MCI).
The main questions it aims to answer are:
Can SuperBrain BOOM be safely and effectively used by people with MCI? Does the program help improve cognitive and physical function? Do participants stay engaged and complete the program as expected?
Researchers will compare:
A mobile intervention group using SuperBrain BOOM (on tablet or smartphone) A control group receiving usual care
Participants will:
Use a tablet or smartphone to follow a personalized physical activity program for 12 weeks Complete clinical assessments on cognition, physical ability, mood, and nutrition Be monitored for safety and program adherence using automatically collected data
Detailed description
This study is designed to assess the feasibility, safety, and potential benefits of a multi-domain personalized physical activity intervention-SuperBrain BOOM-delivered via mobile devices (tablet or smartphone) for individuals with Mild Cognitive Impairment (MCI).
Mild Cognitive Impairment is a condition in which individuals experience noticeable cognitive decline without significant impairment in daily functioning. It is considered a transitional stage between normal aging and dementia. Evidence suggests that regular physical activity and cognitive engagement can delay or reduce the risk of progression to dementia.
SuperBrain BOOM provides personalized exercise programs tailored to each participant's cognitive status, physical capacity, and lifestyle, and is designed to improve cognitive function, physical performance, emotional well-being, and quality of life.
This randomized controlled trial will allocate participants into three groups: a mobile intervention group (tablet or smartphone) and a control group receiving usual care. The primary outcomes include changes in cognitive function, physical performance, mood, nutritional status, and quality of life over 12 weeks. Safety and adherence will be monitored throughout the intervention using system-generated data and clinical assessments.
Secondary analyses will explore subgroup differences based on APOE genotype and demographic variables to better understand who benefits most from the intervention.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Tablet-based intervention group | Experimental | Device: Tablet-based Physical SuperBrain BOOM |
| Smartphone-based intervention group | Experimental | Device: Smartphone-based SuperBrain BOOM |
| Control group | No intervention | – |
Who may qualify
- Ages
- 50 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (16 listed)
- Age: Between 50 and 85 years old.
- Meets all of the core clinical criteria for suspected Mild Cognitive Impairment (MCI) according to the National Institute on Aging-Alzheimer's Association (NIA-AA) guidelines as of the screening date:
- Has one or more of the following neuropsychological test results within one year of the screening date, with delayed recall scores in the memory domain below the mean -1.0 standard deviation according to age- and education-adjusted normative data:
- As of the screening date, has a Korea-Mini Mental State Examination (K-MMSE-2) score that corresponds to at least -1.5 standard deviations below the mean based on age- and education-adjusted normative data.
- As of the screening date, has a Global Clinical Dementia Rating (CDR) score of 0.5, with a memory score of either 0.5 or 1.
Key exclusion criteria (12 listed)
- Presence of psychiatric disorders, such as major depression.
- Dementia.
- Other neurodegenerative diseases, such as Parkinson's disease.
- Malignant tumors within the past 5 years that have not been declared cured.
- Vascular surgery or stent placement within the past year.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tablet-based Physical SuperBrain BOOMThis intervention is a tablet-based physical activity program designed for patients with Mild Cognitive Impairment (MCI). Participants receive a personalized exercise plan through a tablet application, with real-time feedback to enhance cognitive function. Compared to the smartphone-based version, this program is designed to provide a larger interface and structured environment, allowing participants to engage in the program using a tablet at home or in a clinical setting. The app also helps track progress and encourage adherence to the exercise regimen. | Device | Tablet-based intervention group |
| Smartphone-based SuperBrain BOOMThis intervention is a smartphone-based physical activity program designed for MCI patients. Participants receive a personalized exercise plan through a smartphone app, with real-time feedback to enhance cognitive function. Unlike the tablet-based intervention, this program is designed to be more portable and flexible, enabling participants to engage in the program from anywhere using their smartphones. The app also helps track progress and encourage adherence to the exercise regimen. | Device | Smartphone-based intervention group |
Primary outcome
14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14)
Time frame: Baseline (Week 0, pre-intervention) and Week 12 (end of intervention)
The ADAS-cog14 is a comprehensive cognitive assessment tool that includes memory, attention and concentration, planning and executive function, visuoconstruction, and orientation. Scores range from 0 to 90, with higher scores indicating worse cognitive function. The assessment will be conducted at baseline and at the end of the intervention (Week 12).
13 secondary outcomes
Korean Mini-Mental State Examination, 2nd Edition (K-MMSE-2)
Time frame: Screening (within 14 days prior to baseline) and Week 12 (end of intervention)
Clinical Dementia Rating scale - Sum of Boxes (CDR-SB)
Time frame: Screening (within 14 days prior to baseline) and Week 12 (end of intervention)
Korean Instrumental Activities of Daily Living (K-IADL)
Time frame: Screening (within 14 days prior to baseline) and Week 12 (end of intervention)
Timed Up and Go test
Time frame: Baseline (Week 0, pre-intervention) and Week 12 (end of intervention)
30-second Sit-to-Stand Test
Time frame: Baseline (Week 0, pre-intervention) and Week 12 (end of intervention)
2-Minute Step Test
Time frame: Baseline (Week 0, pre-intervention) and Week 12 (end of intervention)
Quality of Life-Alzheimer's Disease (QOL-AD)
Time frame: Screening (within 14 days prior to baseline) and Week 12 (end of intervention)
Nutritional Quotient for Elderly (NQ-E)
Time frame: Baseline (Week 0, pre-intervention) and Week 12 (end of intervention)
Mini Nutritional Assessment (MNA)
Time frame: Baseline (Week 0, pre-intervention) and Week 12 (end of intervention)
Assessment of Metabolic and Vascular Risk Factors
Time frame: Screening (within 14 days prior to baseline) and Week 12 (end of intervention)
Geriatric Depression Scale-15 items (GDS-15)
Time frame: Screening (within 14 days prior to baseline) and Week 12 (end of intervention)
Prospective and Retrospective Memory Questionnaire (PRMQ)
Time frame: Screening (within 14 days prior to baseline) and Week 12 (end of intervention)
Pittsburgh Sleep Quality Index (PSQI)
Time frame: Screening (within 14 days prior to baseline) and Week 12 (end of intervention)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Mild Cognitive Impairment (MCI)
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
RecruitingObservational study
Community-based Screening for Alzheimer's Disease
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
RecruitingObservational study
InRAD Observational Study
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
Recruiting
Treating Insomnia in Mild Cognitive Impairment
Mild Cognitive Impairment (MCI), Insomnia
Recruiting
Telehealth-Adapted Compensatory Training and Intervention for Cognition
MCI, Mild Cognitive Impairment
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
So Young Moon principal investigator
Ajou University School of Medicine
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Tablet-based Physical SuperBrain BOOM and Smartphone-based SuperBrain BOOM in people with Mild Cognitive Impairment (MCI), run by Ajou University School of Medicine at 4 sites in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 16 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14) (time frame: Baseline (Week 0, pre-intervention) and Week 12 (end of intervention)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.